OmniAb licenses antibody discovery technology to pharma and biotech companies, enabling partners to discover fully human antibody candidates for drug development. Partners then take those candidates through clinical development and commercialization independently. At the core of OmniAb's platform are proprietary transgenic animals — rats (OmniRat), mice (OmniMouse), and chickens (OmniChicken) — genetically engineered to produce antibodies with human sequences. OmniAb immunizes these animals with a target antigen, then uses high-throughput single B-cell screening tools to identify the best candidates from millions of cells and delivers leads to partners. OmniAb also offers specialized platforms for bispecific antibodies (OmniFlic/OmniClic), ultralong-domain antibodies (OmniTaur, OmniUltra), and single-domain antibodies (OmnidAb), alongside AI-driven tools (OmniDeep, OmniHub) for antibody optimization. OmniAb earns revenue through technology access fees, service fees for running discovery campaigns, and milestones and royalties as partners advance drugs through development and into commercial sale. Royalties — typically in the low- to mid-single-digit percentage of net sales — represent the long-term value driver. As of late 2025, OmniAb had 107 active partners running 407 programs, with 27 antibodies in clinical development and three approved products. OmniAb also sells its xPloration screening instrument to partners at roughly $500K per unit, with recurring revenue from consumables and software, creating an additional revenue stream alongside its core licensing model.